<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34509895</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Atencion primaria</Title><ISOAbbreviation>Aten Primaria</ISOAbbreviation></Journal><ArticleTitle>[Amyotrophic lateral sclerosis (ALS) from the perspective of Primary Care. Epidemiology and clinical-care characteristics].</ArticleTitle><Pagination><StartPage>102158</StartPage><MedlinePgn>102158</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aprim.2021.102158</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0212-6567(21)00192-X</ELocationID><Abstract><AbstractText Label="UNLABELLED">Amyotrophic Lateral Sclerosis (ALS) is a rare disease in primary care (PC), it represents a challenge for the family doctor, especially in home care.</AbstractText><AbstractText Label="OBJECTIVE">To know the incidence and prevalence of ALS in an area of ??PA management, the clinical characteristics and use of health resources.</AbstractText><AbstractText Label="DESIGN">Observational study.</AbstractText><AbstractText Label="LOCATION">PC-Direction Costa de Ponent, South Metropolitan Health Region, Barcelona, Catalonia, Spain.</AbstractText><AbstractText Label="PARTICIPANTS">Patients with ALS &#x2265;18 years diagnosed until 03/01/2017. Main measurements Age, sex, characteristics: form of appearance (spinal, bulbar, others), interval between onset of symptoms and diagnosis, percutaneous gastrostomy carriers, ventilation non-invasive or invasive. Identification in PC as a Complex Chronic Patient or with palliative needs (CCP). Inclusion in home care programs (PAD). Model of attention hospitable.</AbstractText><AbstractText Label="RESULTS">81 patients, mean age 65.6 years (&#xb1; 11.7), men 49.4%. Shape of onset: spinal 69%, bulbar 21%, another 4%. Interval between the onset of symptoms and diagnosis 12 months. Identified as a CCP 13.6%, 29 patients (35.8%) included in PAD. Attended in comprehensive hospital model 79 patients (97.5%). Prevalence 6.1/100,000 inhabitants in 2017. Annual incidence between 1.2 cases/100,000 inhabitants/year in 2012 and 3.5 cases/100,000 inhabitants/year in 2016.</AbstractText><AbstractText Label="CONCLUSIONS">The use of percutaneous gastrostomy in ALS favors the identification as CCP or with palliative needs and inclusion in PAD. The use of non-invasive ventilation favors inclusion in PAD. The incidence and prevalence data for ALS are higher than those described above in the same area. Early identification is necessary of these patients in the chronic care models in PC teams.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castro-Rodr&#xed;guez</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>PADES Delta de Llobregat, Institut Catal&#xe0; de la Salut, El Prat de Llobregat, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azagra</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centro de Atenci&#xf3;n Primaria Badia del Vall&#xe8;s, Institut Catal&#xe0; de la Salut, Badia del Vall&#xe8;s, Barcelona, Espa&#xf1;a; GROIMAP-USR MN-IDIAP Jordi Gol, Girona, Espa&#xf1;a; Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a; Universitat Internacional de Catalu&#xf1;a, Barcelona, Espa&#xf1;a. Electronic address: razagral@telefonica.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Batiste</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>C&#xe1;tedra de Cuidados Paliativos, Centre d'Estudis Sanitaris i Socials (CESS), Universitat de Vic - Universitat Central de Catalunya (UVIC-UCC), Vic, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Neuromuscular, Servicio de Neurolog&#xed;a, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>La esclerosis lateral amiotr&#xf3;fica (ELA) desde la Atenci&#xf3;n Primaria. Epidemiolog&#xed;a y caracter&#xed;sticas cl&#xed;nico-asistenciales.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Aten Primaria</MedlineTA><NlmUniqueID>9111075</NlmUniqueID><ISSNLinking>0212-6567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Aten Primaria. 2022 May;54(5):102322</RefSource><PMID Version="1">35325790</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006699" MajorTopicYN="Y">Home Care Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="UNLABELLED">La ELA es una enfermedad poco frecuente en atenci&#xf3;n primaria (AP), representa un desaf&#xed;o para el m&#xe9;dico de familia especialmente en atenci&#xf3;n domiciliaria.</AbstractText><AbstractText Label="OBJETIVO">Conocer la incidencia y prevalencia de la ELA en un &#xe1;rea de gesti&#xf3;n de AP, las caracter&#xed;sticas cl&#xed;nicas y la utilizaci&#xf3;n de recursos sanitarios.</AbstractText><AbstractText Label="DISE&#xd1;O">Estudio observacional.</AbstractText><AbstractText Label="EMPLAZAMIENTO">Direcci&#xf3;n de AP Costa de Ponent, Regi&#xf3;n Sanitaria Metropolitana Sur, Barcelona, Catalu&#xf1;a, Espa&#xf1;a.</AbstractText><AbstractText Label="PARTICIPANTES">Pacientes con ELA &#x2265;18 a&#xf1;os diagnosticados hasta el 01/03/2017.</AbstractText><AbstractText Label="MEDICIONES PRINCIPALES">Edad, sexo, caracter&#xed;sticas: forma de inicio (espinal, bulbar, otras), intervalo entre inicio de s&#xed;ntomas y diagn&#xf3;stico, portadores gastrostom&#xed;a percut&#xe1;nea, ventilaci&#xf3;n no invasiva o invasiva. Identificaci&#xf3;n en AP como paciente cr&#xf3;nico complejo o con necesidades paliativas. Inclusi&#xf3;n en programas de atenci&#xf3;n domiciliaria (PAD). Modelo de atenci&#xf3;n hospitalario.</AbstractText><AbstractText Label="RESULTADOS">Ochenta y un pacientes, edad media 65,6 a&#xf1;os (&#xb1;11,7), varones 49,4%. Forma de inicio: espinal 69%, bulbar 21%, otras 4%. Intervalo entre inicio de s&#xed;ntomas y diagn&#xf3;stico 12 meses. Identificados como paciente cr&#xf3;nico complejo o con necesidades paliativas 13,6%, incluidos en PAD 29 pacientes (35,8%). Atendidos en modelo hospitalario integral 79 pacientes (97,5%). Prevalencia 6,1/100.000 habitantes en 2017. Incidencia anual entre 1,2 casos/100.000 habitantes/a&#xf1;o en 2012 y 3,5 casos/100.000 habitantes/a&#xf1;o en 2016.</AbstractText><AbstractText Label="CONCLUSIONES">Utilizar gastrostom&#xed;a percut&#xe1;nea en la ELA favorece la identificaci&#xf3;n como paciente cr&#xf3;nico complejo o con necesidades paliativas e inclusi&#xf3;n en PAD. Utilizar ventilaci&#xf3;n no invasiva favorece la inclusi&#xf3;n en PAD. Los datos de incidencia y prevalencia de ELA son superiores a los descritos previamente en la misma &#xe1;rea. Es necesaria la identificaci&#xf3;n precoz de estos pacientes en los modelos de atenci&#xf3;n a la cronicidad en equipos de AP.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Atenci&#xf3;n domiciliaria</Keyword><Keyword MajorTopicYN="N">Atenci&#xf3;n primaria</Keyword><Keyword MajorTopicYN="N">Chronicity</Keyword><Keyword MajorTopicYN="N">Cronicidad</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Epidemiolog&#xed;a</Keyword><Keyword MajorTopicYN="N">Esclerosis lateral amiotr&#xf3;fica</Keyword><Keyword MajorTopicYN="N">Home care service</Keyword><Keyword MajorTopicYN="N">Primary health care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>12</Day><Hour>20</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34509895</ArticleId><ArticleId IdType="pmc">PMC8435918</ArticleId><ArticleId IdType="doi">10.1016/j.aprim.2021.102158</ArticleId><ArticleId IdType="pii">S0212-6567(21)00192-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:1&#x2013;18.</Citation></Reference><Reference><Citation>Marin B., Boumediene F., Logroscino G., Couratier P., Babron M.C., Leutenegger A.L. Variation in worldwide incidence of amyotrophic lateral sclerosis: a metaanalysis. Int J Epidemiol. 2017;46:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradas J., Puig T., Rojas-Garcia R., Viguera M.L., Gich I., Logroscino G. Amyotrophic lateral sclerosis in Catalonia: a population based study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">23286747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., van Den Berg L.H., Kiernan M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83:102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., van den Berg L.H., Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J., Callagher P., Gardham J., Mitchell C., Dixon M., Addison Jones R. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) a 20-year review: Can we do better? Amyotroph Lateral Scler. 2010;11:537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">20565332</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Costa J., Mart&#xed;nez-Molina M., Fern&#xe1;ndez-Polo M., Forn&#xe9;s-Ferrer V., Frasquet-Carrera M., Sevilla-Mantec&#xf3;n T. An&#xe1;lisis del trayecto y retraso diagn&#xf3;stico de los pacientes con esclerosis lateral amiotr&#xf3;fica en la Comunidad Valenciana. Neurolog&#xed;a. 2017 [consultado 2 Oct 2020]. Disponible en: https://www.elsevier.es/es-revista-neurologia-295-estadisticas-S0213485318301579.</Citation></Reference><Reference><Citation>Dorst J., Ludolph A.C., Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2018;11:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012:CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S., Trevor-Jones E., Khan S., Shaw K., Marchment D., Kulka A. The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:569&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">28719997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson E.V., McDermott C.J. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12:526&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">27514291</ArticleId></ArticleIdList></Reference><Reference><Citation>Paipa A.J., Povedano M., Barcel&#xf3; A., Dom&#xed;nguez R., Saez M., Turon J. Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in Spain: association with noninvasive mechanical ventilation. J Multidiscip Healthc. 2019;12:465&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590410</ArticleId><ArticleId IdType="pubmed">31354285</ArticleId></ArticleIdList></Reference><Reference><Citation>Blay C., Lim&#xf3;n E., Albuquerque J., Ambl&#xe0;s J., Ansa X., Ari&#xf1;o S. Bases para un modelo catal&#xe1;n de atenci&#xf3;n a las personas con necesidades complejas: conceptualizaci&#xf3;n e introducci&#xf3;n a los elementos operativos. 2017 [consultado 2 Oct 2020]. Disponible en: https://salutweb.gencat.cat/web/.content/_ambits-actuacio/Linies-dactuacio/Estrategies-de-salut/Cronicitat/Documentacio-cronicitat/arxius/bases_modelo_personas_complejidad_v_6.pdf.</Citation></Reference><Reference><Citation>G&#xf3;mez-Batiste X., Mart&#xed;nez-Mu&#xf1;oz M., Blay C., Ambl&#xe0;s J., Vila L., Costa X. Identificaci&#xf3;n de personas con enfermedades cr&#xf3;nicas avanzadas y necesidad de atenci&#xf3;n paliativa en servicios sanitarios y sociales: elaboraci&#xf3;n del instrumento NECPAL CCOMS-ICO&#xa9;. Med Clin (Barc). 2013;140:241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">23103110</ArticleId></ArticleIdList></Reference><Reference><Citation>Departament de Salut Generalitat de Catalunya Pla salut de Catalunya 2016-2020. Generalitat de Catalunya. 2016 [consultado 2 Oct 2020].Disponible en: https://salutweb.gencat.cat/web/.content/_departament/pla-de-salut/Pla-de-salut-2016-2020/documents/Pla_salut_Catalunya_2016-2020.pdf.</Citation></Reference><Reference><Citation>Garc&#xe9;s J., R&#xf3;denas F. La gesti&#xf3;n de casos como metodolog&#xed;a para la conexi&#xf3;n de los sistemas sanitario y social en Espa&#xf1;a. Aten Primaria. 2015;47:482&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6983701</ArticleId><ArticleId IdType="pubmed">25559564</ArticleId></ArticleIdList></Reference><Reference><Citation>Aproximaci&#xf3;n a la atenci&#xf3;n domiciliaria &#xbf;C&#xf3;mo trabaja la sanidad p&#xfa;blica catalana la atenci&#xf3;n domiciliaria? Grupo ATDOM de la Sociedad Catalana de Medicina Familiar i Comunitaria. Aten Primaria. 2003;31:473&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7681841</ArticleId><ArticleId IdType="pubmed">12765583</ArticleId></ArticleIdList></Reference><Reference><Citation>Busquets X. Los equipos de soporte y la atenci&#xf3;n domiciliaria de enfermos terminales. FMC: Formaci&#xf3;n M&#xe9;dica Continuada en Atenci&#xf3;n Primaria. 2001;8:543&#x2013;550.</Citation></Reference><Reference><Citation>Epidemiolog&#xed;a en la pr&#xe1;ctica m&#xe9;dica, 2.&#xa0;&#xaa; edici&#xf3;n. DJP Barker y G. Barcelona: Rose Masson-Salvat Medicina, 1992.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>